Hence, it is tempting to speculate that tamoxifen efficacy in delaying the reoccurrence of breast cancer is due, in part, to its collateral sensitivity effect to selectively target P-gp overexpressing breast cancer cells. This evidence concerns the gene PGP and breast carcinoma.